Gilead Sciences Buys Kite Pharma For $11.9 Billion: New Lymphoma Cancer Treatment In Works

New Treatments for Lymphoma Blood Cancer

Biopharmaceutical leader Gilead Sciences will buy Kite Pharma, Inc. for $ 11.9 billion later this year, both companies announced Monday. Gilead is the maker of biopharma drugs like Tamiflu®, Harvoni®, and others regarded as market-leading HIV/AIDS and Hepatitis C treatments. The sale indicates that Kite Pharma’s innovative cancer treatment is likely to be approved for use by patients with non-Hodgkin lymphoma in 2017.

The acquisition expands Gilead’s ability to develop cancer treatments, a renewed direction for the pharma industry leader. Kite Pharma’s cell therapy for non-Hodgkin lymphoma is under review by the U.S. Food & Drug Administration. The treatment, called CAR T-cell therapy, enables a patient’s own immune cells to fight cancer cells. Non-Hodgkin lymphoma, a blood cancer, is one of the most common cancers in the U.S., accounting for more than 4 percent of new cases each year.

Click here to continue and read more…

The Inquisitr